Sherko Kummel

Sherko Kummel is a breast surgeon and clinical researcher who has contributed to neoadjuvant studies in triple-negative breast cancer including rare metaplastic subtype analyses, studying whether adding checkpoint inhibitors to chemotherapy backbones can overcome the intrinsic chemoresistance of metaplastic tumors. His translational studies have investigated PD-L1 expression and tumor mutational burden as predictors of immune checkpoint response in metaplastic breast carcinoma. He participates in collaborative German Breast Group neoadjuvant platform trials.